6-iodo-D-fucose | 18465-34-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-iodo-D-fucose
• 英文别名: D-galacto-2,3,4,5-Tetrahydroxy-6-jod-hexanal；6-Jod-6-desoxy-D-galactose；6-Jod-D-fucose；6-Iodo-6-deoxy-d-galactose；(2R,3S,4R,5S)-2,3,4,5-tetrahydroxy-6-iodohexanal
• CAS: 18465-34-4
• 化学式: C₆H₁₁IO₅
• 分子量: 290.055
• InChiKey: LEEXPFSMMOTNIJ-DPYQTVNSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  98
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  6-脱氧-6-碘-1,2:3,4-二-o-异亚丙基-α-d-半乳糖吡喃糖苷 在 溶剂黄146 作用下， 生成 6-iodo-D-fucose
  参考文献：
  名称：

  Synthesis of Some Iodo-sugar Derivatives¹

  摘要：

  DOI：

  10.1021/ja01188a045

文献信息

• METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION
  申请人：Seattle Genetics, Inc.

  公开号：US20140031536A1

  公开（公告）日：2014-01-30

  The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.

  这项发明提供了一种减少核心岩藻糖基化的抗体和抗体衍生物制备的方法和组合物。
• MODIFIED GLYCOPROTEIN, PROTEIN-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF
  申请人：SYNAFFIX B.V.

  公开号：US20160250347A1

  公开（公告）日：2016-09-01

  Glycoproteins comprising a glycan of the formula (102) are disclosed; wherein b is 0 or 1; the GlcNAc residue optionally fucosylated; and Su(A) x is a sugar derivative comprising x functional groups A, wherein x is 1, 2, 3 or 4 and A is independently selected from the group consisting of an azido group, a keto group, an alkynyl group, a thiol group, a halogen, a sulfonyloxy group, a halogenated acetamido group, a mercaptoacetamido group and a sulfonylated hydroxyacetamido group. Protein-conjugates having glycoproteins according to the invention conjugated to a molecule of interest (e.g., an active substance) are also disclosed. Examples include modified antibodies, antibody-conjugates, and antibody-drug conjugates (ADCs). Processes for the preparation of the modified glycoproteins according to the invention and methods for the preparation of a protein-conjugate according to the invention are mentioned.

  本发明揭示了一种包含公式（102）的糖蛋白；其中b为0或1；GlcNAc残基可以选择性地被岩藻糖基化；Su（A）是一种糖衍生物，包括x个功能基团A，其中x为1、2、3或4，A独立地选择自由基组，包括偶氮基、酮基、炔基、硫醇基、卤素、磺酰氧基、卤代乙酰胺基、巯基乙酰胺基和磺酰化羟基乙酰胺基。 本发明还揭示了将本发明中的糖蛋白共轭到感兴趣的分子（例如，活性物质）上的蛋白质共轭物。例如，包括改性抗体、抗体共轭物和抗体药物共轭物（ADC）。还提及了制备本发明中改性糖蛋白的方法以及制备本发明中蛋白质共轭物的方法。
• Modified glycoprotein, protein-conjugate and process for the preparation thereof
  申请人：SynAffix B.V.

  公开号：US10072096B2

  公开（公告）日：2018-09-11

  The invention relates to a glycoprotein comprising an optionally fucosylated glycan according to formula (105) or (106), wherein Su(A)x is a modified sugar moiety comprising one or more functional groups A. Functional group A is independently selected from the group consisting of a thiol group, a halogen, a sulfonyloxy group, a halogenated acetamido group, a mercaptoacetamido group and a sulfonated hydroxyacetamido group. The invention also relates to a glycoprotein-conjugate wherein a glycoprotein according to the invention is conjugated to a molecule of interest. Said molecule of interest may for example be an active substance. The invention further relates to a process for the preparation of a modified glycoprotein, and to a method for the preparation of a glycoprotein-conjugate. The invention particularly relates to modified antibodies, antibody-conjugates, antibody-drug conjugates and methods for the preparation thereof.

  本发明涉及一种糖蛋白，该糖蛋白包含符合式（105）或（106）的可选岩藻糖基化聚糖，其中Su(A)x是包含一个或多个官能团A的修饰糖分子，官能团A独立地选自硫醇基、卤素、磺酰氧基、卤代乙酰氨基、巯基乙酰氨基和磺化羟基乙酰氨基组成的组。本发明还涉及一种糖蛋白-共轭物，其中根据本发明的糖蛋白与相关分子共轭。所述相关分子可以是活性物质。本发明还涉及一种制备修饰糖蛋白的工艺，以及一种制备糖蛋白-结合物的方法。本发明尤其涉及修饰的抗体、抗体-轭合物、抗体-药物轭合物及其制备方法。
• Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
  申请人：SEATTLE GENETICS, INC.

  公开号：US10443035B2

  公开（公告）日：2019-10-15

  The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.

  本发明提供了制备核心岩藻糖基化减少的抗体和抗体衍生物的方法和组合物。
• MEDICAL IMPLANT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS
  申请人：Interstitial Therapeutics

  公开号：EP1789030A2

  公开（公告）日：2007-05-30